Non-psoriatic dermatologic uses of monoclonal antibody therapy

References

• Bohm M, Luger TA. 2007; Lichen planus responding to efalizumab. J Am Acad Dermatol. 56:S92–3.
   PubMed Web of Science ®Google Scholar
• Cheng A, Mann C. 2006; Oral erosive lichen planus treated with efalizumab. Arch Dermatol. 142:680–2.
   PubMedGoogle Scholar
• Micromedex Healthcare Series (Drugdex). Drug Summary: 1974-2009. Thompson Healthcare. Montvale, New Jersey.
   Google Scholar
• Fernández-vozmediano JM, Armario-hita JC. 2007; Infliximab for the treatment of hidradenitis suppurativa.. Dermatology. 215:41–4.
   PubMedGoogle Scholar
• Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, 2007; Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 56:624–8.
   PubMed Web of Science ®Google Scholar
• Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, 2006; Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut. 55:505–9.
   PubMed Web of Science ®Google Scholar
• Kouklakis G, Moschos J, Leontiadis GI, Kadis S, Mpoumponaris A, Molyvas E, 2005; Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol. 14:401–3.
   PubMedGoogle Scholar
• Shirakawa M, Uramoto K, Harada FA. 2006; Treatment of acne conglobata with infliximab.. J Am Acad Dermatol. 55:344–6.
   PubMed Web of Science ®Google Scholar
• Kreuter A, Gambichler T, Altmeyer P. 2007; Infliximab therapy for interstitial granulomatous dermatitis.. J Eur Acad Dermatol Venereol. 21:251–2.
   PubMed Web of Science ®Google Scholar
• Vega Gutierrez, J Rodriguez, Prieto MA, Garcia Ruiz JM. 2007; Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol. 21:570–1.
   PubMed Web of Science ®Google Scholar
• Clayton TH, Walker BP, Stables GI. 2006; Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol. 31:823–4.
   PubMed Web of Science ®Google Scholar
• Faber WR, Jensema AJ, Goldschmidt WF. 2006; Treatment of recurrent erythema nodosum leprosum with infliximab.. N Engl J Med. 355:739.
   Google Scholar
• Streit M, Beleznay Z, Braathen LR. 2006; Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J. 3:171–9.
   PubMedGoogle Scholar
• Heffernan MP, Bentley DD. 2006; Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol. 142:1268–70.
   PubMedGoogle Scholar
• Ruiz-genao DP, Lopez-estebaranz JL, Naz-villalba E, Gamo-villegas R, Calzado-villarreal L, Pinedo-moraleda F. 2007; Pityriasis rubra pilaris successfully treated with infliximab. Acta Derm Venereol. 87:552–3.
   Google Scholar
• Simon JA, Burgos-vargas R. 2008; Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology. 216:234–5.
   PubMed Web of Science ®Google Scholar
• Heffernan MP, Anadkat MJ, Smith DI. 2007; Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 143:306–8.
   PubMedGoogle Scholar
• Pomerantz RG, Husni ME, Mody E, Qureshi AA. 2007; Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 157:1274–5.
   PubMed Web of Science ®Google Scholar
• Ortego-centeno N, Callejas-rubio JL, Sanchez-cano D, Caballero-morales T. 2007; Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol. 21:408–10.
   PubMed Web of Science ®Google Scholar
• Moul DK, Korman NJ. 2006; The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 142:110–12.
   Google Scholar
• Philips MA, Lynch J, Azmi FH. 2005; Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 53:917.
   PubMed Web of Science ®Google Scholar
• Mankad VS, Burks AW. 2005; Omalizumab: Other indications and unanswered questions. Clin Rev Allergy Immunol. 29:17–30.
   PubMed Web of Science ®Google Scholar
• Andres C, Belloni B, Mempel M, Ring J. 2008; Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep. 8:179–80.
   PubMed Web of Science ®Google Scholar
• Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. 2006; Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 55:168–70.
   PubMed Web of Science ®Google Scholar
• Spector SL, Tan RA. 2008; Omalizumab also successful in chronic urticaria. J Allergy Clin Immunol. 121:784–.
   Google Scholar
• Metz M, Bergmann P, Zuberbier T, Maurer M. 2008; Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 63:247–9.
   PubMed Web of Science ®Google Scholar
• Siebenhaar F, Kuhn W, Zuberbier T, Maurer M. 2007; Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol. 120:213–15.
   PubMed Web of Science ®Google Scholar
• Allen KJ, Wolverton SE. 2007; The efficacy and safety of rituximab in refractory pemphigus: A review of case reports. J Drugs Dermatol. 6:883–9.
   PubMedGoogle Scholar
• Diaz LA. 2007; Rituximab and pemphigus - A therapeutic advance. N Engl J Med. 357:605–7.
   Google Scholar
• El Tal Ak, Posner MR, Spigelman Z, Ahmed AR. 2006; Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 55:449–59.
   Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. 2006; Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 355:1772–9.
   PubMed Web of Science ®Google Scholar
• Goh MS, Mccormack C, Dinh HV, Welsh B, Foley P, Prince HM. 2007; Rituximab in the adjuvant treatment of pemphigus vulgaris: A prospective open-label pilot study in five patients. Br J Dermatol. 156:990–6.
   PubMed Web of Science ®Google Scholar
• Faurschou A, Gniadecki R. 2008; Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 47:292–4.
   PubMed Web of Science ®Google Scholar
• Fernando SL, O'connor KS. 2008; Treatment of severe pemphigus foliaceus with rituximab. Med J Aust. 189:289–90.
   PubMed Web of Science ®Google Scholar
• Serrao VV, Martins A, Paris FR, Lopes MP. 2008; Successful treatment of recalcitrant pemphigus foliaceus with rituximab. J Eur Acad Dermatol Venereol. 22:768–70.
   PubMed Web of Science ®Google Scholar
• Levine TD. 2005; Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum. 52:601–7.
   PubMed Web of Science ®Google Scholar
• Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. 2007; Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects. Br J Dermatol. 156:352–6.
   PubMed Web of Science ®Google Scholar
• Saouli Z, Papadopoulos A, Kaiafa G, Girtovitis F, Kontoninas Z. 2008; A new approach on bullous pemphigoid therapy. Ann Oncol. 19:825–6.
   Google Scholar
• Crichlow SM, Mortimer NJ, Harman KE. 2007; A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 156:194–6.
   PubMed Web of Science ®Google Scholar
• Wallet-faber N, Franck N, Batteux F, Mateus C, Gilbert D, Carlotti A, 2007; Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology. 215:252–5.
   PubMed Web of Science ®Google Scholar
• Ferrer E, Moral MA. 2006; Spotlight on rituximab as a new therapeutic option for dermatomyositis and thrombotic thrombocytopenic purpura. Drug News Perspect. 19:482–4.
   Google Scholar
• Gitelson E, Al-saleem T, Millenson M, Lessin S, Smith MR. 2006; Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leuk Lymphoma. 47:1902–7.
   PubMed Web of Science ®Google Scholar
• Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, et al. 2006; Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 77:300–3.
   PubMed Web of Science ®Google Scholar
• Hertl M, Zillikens D, Borradori L, Bruckner-tuderman L, Burckhard H, Eming R, 2008; Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 6:366–73.
   PubMed Web of Science ®Google Scholar